MCP-1 AND VITAMIN D PROFILES IN ESRD ON HEMODIALYSIS: A CASE-CONTROL STUDY IN AL-BASRAH CITY
Downloads
Objective: This study aimed to examine and compare serum levels of vitamin D and monocyte chemoattractant protein-1 (MCP-1) in patients with end-stage renal disease (ESRD) undergoing haemodialysis versus healthy individuals, and to evaluate their diagnostic potential as biomarkers. Method: An observational cross-sectional design was employed involving 30 ESRD patients receiving regular haemodialysis and 34 age- and sex-matched healthy controls. Serum levels of vitamin D, MCP-1, parathyroid hormone (PTH), urea, creatinine, estimated glomerular filtration rate (eGFR), and blood pressure were assessed. Results: ESRD patients showed significantly elevated levels of urea, creatinine, PTH, and MCP-1, and significantly lower eGFR and vitamin D levels compared to controls (p<0.001). ROC analysis revealed high diagnostic accuracy for PTH (AUC=0.946), with moderate-to-good performance for vitamin D (AUC=0.732) and MCP-1 (AUC=0.700). Novelty: This study contributes to the limited regional data by identifying the potential of vitamin D and MCP-1 as accessible clinical biomarkers for nutritional and inflammatory assessment in ESRD patients undergoing haemodialysis, emphasizing their role in early detection strategies and patient monitoring.
C. P. Kovesdy, “Epidemiology of chronic kidney disease: An update 2022,” Kidney International Supplements, vol. 12, no. 1, pp. 7–11, 2022, doi: 10.1016/j.kisu.2021.11.003.
Y. Raad Humudat, “Assessment of the impact of anemia on hematological parameters among hemodialysis patients with chronic kidney disease,” Bionatura, vol. 8, no. 1, pp. 1–5, 2023, doi: 10.21931/rb/2023.08.01.32.
K. J. Jager, C. Kovesdy, R. Langham, M. Rosenberg, V. Jha, and C. Zoccali, “A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases,” Nephrology Dialysis Transplantation, vol. 34, no. 11, pp. 1803–1805, 2019, doi: 10.1093/ndt/gfz174.
N. Latic and R. G. Erben, “Vitamin D and Cardiovascular Disease, with Emphasis on Hypertension, Atherosclerosis, and Heart Failure,” International Journal of Molecular Sciences, vol. 21, no. 18, pp. 6483–6498, 2020, doi: 10.3390/ijms21186483.
A. Etminan, S. Mostafa, A. N. Tahami, S. Mahdi, M. Behzadi, and M. Shabani, “Relationship between the serum levels of Vitamin D and inflammatory markers in ESRD patients.,” PubMed, vol. 91, no. 4, pp. 1–7, 2020, doi: 10.23750/abm.v91i4.8223.
S. Kumar, B. Das, S. Kumar, A. M. Junejo, R. Memon, and O. Lal, “Vitamin D Deficiency in End-Stage Renal Disease Patients on Maintenance Hemodialysis,” Pakistan Journal of Medical and Health Sciences, vol. 16, no. 1, pp. 365–366, 2022, doi: 10.53350/pjmhs22161365.
K. Seshadri, P. Radhakrishnan, P. Srikanth, R. Barani, and M. Samanta, “Serum monocyte chemoattractant protein-1 is a biomarker in patients with diabetes and periodontitis,” Indian Journal of Endocrinology and Metabolism, vol. 18, no. 4, pp. 505–510, 2014, doi: 10.4103/2230-8210.137498.
A. Papayianni et al., “Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events,” Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association, vol. 17, no. 3, pp. 435–441, 2002, doi: 10.1093/ndt/17.3.435.
S. L. Deshmane, S. Kremlev, S. Amini, and B. E. Sawaya, “Monocyte Chemoattractant Protein-1 (MCP-1): An Overview,” Journal of Interferon & Cytokine Research, vol. 29, no. 6, pp. 313–326, 2009, doi: 10.1089/jir.2008.0027.
Y. Liu et al., “Role of MCP-1 as an inflammatory biomarker in nephropathy,” Frontiers in Immunology, vol. 14, p. 1303076, 2023, doi: 10.3389/fimmu.2023.1303076.
L. Parker Gregg, M. Tio, X. Li, B. Adams-Huet, James A. de Lemos, and S. Susan Hedayati, “Association of Monocyte Chemoattractant Protein-1 with Death and Atherosclerotic Events in Chronic Kidney Disease,” American Journal of Nephrology, vol. 47, no. 6, pp. 395–405, 2018, doi: 10.1159/000488806.
P. E. Stevens et al., “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,” Kidney International, vol. 105, no. 4, pp. 117–314, 2024, doi: 10.1016/j.kint.2023.10.018.
DJ Chew, “Schenck PA. Renal Anatomy, Physiology, and Evaluation of Function,” ANATOMY OF THE KIDNEY, pp. 1-36, 2023.
C. M. Rebholz et al., “Risk of ESRD and Mortality Associated With Change in Filtration Markers,” American Journal of Kidney Diseases, vol. 70, no. 4, pp. 551–560, 2017, doi: 10.1053/j.ajkd.2017.04.025.
C. S. Kim et al., “Cumulative hypertension burden and risk of end-stage renal disease,” Hypertension Research, vol. 44, no. 12, pp. 1652–1661, 2021, doi: 10.1038/s41440-021-00723-0.
H. S. Jørgensen et al., “The role of nutritional vitamin D in CKD-MBD in children and adults with CKD, on dialysis and after kidney transplantation – a European consensus statement,” Nephrology Dialysis Transplantation, vol. 40, no. 4, pp. 797–822, 2025, doi: 10.1093/ndt/gfae293.
Y. Wang et al., “Association between serum vitamin D and the risk of diabetic kidney disease in patients with type 2 diabetes,” Frontiers in Medicine, vol. 11, 2024, doi: 10.3389/fmed.2024.1445487.
EslamA. M. El-Khalifa, A. El-Arbagy, KhaledM. A. El-Zorkany, and M. Helwa, “Assessment of vitamin D in hemodialysis patients,” Menoufia Medical Journal, vol. 33, no. 1, pp. 122–126, 2020, doi: 10.4103/mmj.mmj_317_18.
V. D. Raikou, V. Kardalinos, and D. Kyriaki, “The Relationship of Residual Renal Function with Cardiovascular Morbidity in Hemodialysis Patients and the Potential Role of Monocyte Chemoattractant Protein-1,” Kidney Diseases, vol. 4, no. 1, pp. 20–28, 2017, doi: 10.1159/000484603.
Copyright (c) 2025 Gufran Abdulkareem, Rana Dawood Salman , Jubran Khaleel Hasan
This work is licensed under a Creative Commons Attribution 4.0 International License.
